Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016, Article ID 1720621, 10 pages
http://dx.doi.org/10.1155/2016/1720621
Review Article

Alpha-Synuclein in Parkinson’s Disease: From Pathogenetic Dysfunction to Potential Clinical Application

Department of Neurology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China

Received 15 April 2016; Revised 3 July 2016; Accepted 10 July 2016

Academic Editor: Shu Wen

Copyright © 2016 Lingjia Xu and Jiali Pu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. G. Meissner, M. Frasier, T. Gasser et al., “Priorities in Parkinson's disease research,” Nature Reviews Drug Discovery, vol. 10, no. 5, pp. 377–393, 2011. View at Publisher · View at Google Scholar
  2. W. Peelaerts, L. Bousset, A. Van der Perren et al., “α-synuclein strains cause distinct synucleinopathies after local and systemic administration,” Nature, vol. 522, no. 7556, pp. 340–344, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Wakabayashi, K. Tanji, S. Odagiri, Y. Miki, F. Mori, and H. Takahashi, “The Lewy body in Parkinson's disease and related neurodegenerative disorders,” Molecular Neurobiology, vol. 47, no. 2, pp. 495–508, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation in the α-synuclein gene identified in families with Parkinson's disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. E.-K. Tan, V. R. Chandran, S. Fook-Chong et al., “Alpha-synuclein mRNA expression in sporadic Parkinson's disease,” Movement Disorders, vol. 20, no. 5, pp. 620–623, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Angot, J. A. Steiner, C. M. Tomé et al., “Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo,” PLoS ONE, vol. 7, no. 6, Article ID e39465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Recasens and B. Dehay, “Alpha-synuclein spreading in Parkinson’s disease,” Frontiers in Neuroanatomy, vol. 8, article 159, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. H. T. Tran, C.-Y. Chung, M. Iba et al., “α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration,” Cell Reports, vol. 7, no. 6, pp. 2054–2065, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. B. S. Connolly and A. E. Lang, “Pharmacological treatment of Parkinson disease: a review,” The Journal of the American Medical Association, vol. 311, no. 16, pp. 1670–1683, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Dehay, M. Bourdenx, P. Gorry et al., “Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations,,” The Lancet Neurology, vol. 14, no. 8, pp. 855–866, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. H. A. Lashuel, C. R. Overk, A. Oueslati, and E. Masliah, “The many faces of α-synuclein: from structure and toxicity to therapeutic target,” Nature Reviews Neuroscience, vol. 14, no. 1, pp. 38–48, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Jakes, M. G. Spillantini, and M. Goedert, “Identification of two distinct synucleins from human brain,” FEBS Letters, vol. 345, no. 1, pp. 27–32, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Krüger, W. Kuhn, T. Müller et al., “Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease,” Nature Genetics, vol. 18, no. 2, pp. 106–108, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban et al., “The new mutation, E46K, of α-synuclein causes parkinson and lewy body dementia,” Annals of Neurology, vol. 55, no. 2, pp. 164–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Appel-Cresswell, C. Vilarino-Guell, M. Encarnacion et al., “Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease,” Movement Disorders, vol. 28, no. 6, pp. 811–813, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Lesage, M. Anheim, F. Letournel et al., “G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome,” Annals of Neurology, vol. 73, no. 4, pp. 459–471, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Pasanen, L. Myllykangas, M. Siitonen et al., “A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology,” Neurobiology of Aging, vol. 35, no. 9, pp. 2180.e1–2180.e5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. J. M. George, “The synucleins,” Genome Biology, vol. 3, Article ID REVIEWS3002, 2002. View at Google Scholar · View at Scopus
  19. B. I. Giasson, I. V. J. Murray, J. Q. Trojanowski, and V. M.-Y. Lee, “A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly,” The Journal of Biological Chemistry, vol. 276, no. 4, pp. 2380–2386, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Games, E. Valera, B. Spencer et al., “Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models,” Journal of Neuroscience, vol. 34, no. 28, pp. 9441–9454, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. D. E. Mor, S. E. Ugras, M. J. Daniels, and H. Ischiropoulos, “Dynamic structural flexibility of α-synuclein,” Neurobiology of Disease, vol. 88, pp. 66–74, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Bartels, J. G. Choi, and D. J. Selkoe, “α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation,” Nature, vol. 477, no. 7362, pp. 107–110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Burré, M. Sharma, T. Tsetsenis, V. Buchman, M. R. Etherton, and T. C. Südhof, “α-Synuclein promotes SNARE-complex assembly in vivo and in vitro,” Science, vol. 329, no. 5999, pp. 1663–1667, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Burré, S. Vivona, J. Diao, M. Sharma, A. T. Brunger, and T. C. Südhof, “Properties of native brain α-synuclein,” Nature, vol. 498, no. 7453, pp. E4–E6, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. H. E. A. Reish and D. G. Standaert, “Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease,” Journal of Parkinson's Disease, vol. 5, no. 1, pp. 1–19, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Lee, S.-Y. Lee, E.-N. Lee, C.-S. Chang, and S. R. Paik, “α-synuclein exhibits competitive interaction between calmodulin and synthetic membranes,” Journal of Neurochemistry, vol. 82, no. 5, pp. 1007–1017, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. V. M. Nemani, W. Lu, V. Berge et al., “Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis,” Neuron, vol. 65, no. 1, pp. 66–79, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. N. M. Bonini and B. I. Giasson, “Snaring the function of α-synuclein,” Cell, vol. 123, no. 3, pp. 359–361, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Chandra, G. Gallardo, R. Fernández-Chacón, O. M. Schlüter, and T. C. Südhof, “α-Synuclein cooperates with CSPα in preventing neurodegeneration,” Cell, vol. 123, no. 3, pp. 383–396, 2005. View at Publisher · View at Google Scholar
  30. J. Burré, M. Sharma, and T. C. Südhof, “Definition of a molecular pathway mediating α-synuclein neurotoxicity,” Journal of Neuroscience, vol. 35, no. 13, pp. 5221–5232, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. K. A. Conway, J. D. Harper, and P. T. Lansbury, “Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease,” Nature Medicine, vol. 4, no. 11, pp. 1318–1320, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. K. A. Conway, S.-J. Lee, J.-C. Rochet, T. T. Ding, R. E. Williamson, and P. T. Lansbury Jr., “Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 2, pp. 571–576, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. D. P. Karpinar, M. B. G. Balija, S. Kügler et al., “Pre-fibrillar α-synuclein variants with impaired Β-structure increase neurotoxicity in parkinson's disease models,” The EMBO Journal, vol. 28, no. 20, pp. 3256–3268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. A. Rodriguez, M. I. Ivanova, M. R. Sawaya et al., “Structure of the toxic core of α-synuclein from invisible crystals,” Nature, vol. 525, no. 7570, pp. 486–490, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. T. S. Ulmer, A. Bax, N. B. Cole, and R. L. Nussbaum, “Structure and dynamics of micelle-bound human α-synuclein,” The Journal of Biological Chemistry, vol. 280, no. 10, pp. 9595–9603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Hoyer, D. Cherny, V. Subramaniam, and T. M. Jovin, “Impact of the acidic C-terminal region comprising amino acids 109-140 on α-synuclein aggregation in vitro,” Biochemistry, vol. 43, no. 51, pp. 16233–16242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Li, N. West, E. Colla et al., “Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 6, pp. 2162–2167, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Samuel, W. P. Flavin, S. Iqbal et al., “Effects of serine 129 phosphorylation on alpha-synuclein aggregation, membrane association, and internalization,” Journal of Biological Chemistry, vol. 291, no. 9, pp. 4374–4385, 2016. View at Publisher · View at Google Scholar
  39. K. J. Inglis, D. Chereau, E. F. Brigham et al., “Polo-like kinase 2 (PLK2) phosphorylates α-synuclein at serine 129 in central nervous system,” The Journal of Biological Chemistry, vol. 284, no. 5, pp. 2598–2602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. J. M. Souza, B. I. Giasson, Q. Chen, V. M.-Y. Lee, and H. Ischiropoulos, “Dityrosine cross-linking promotes formation of stable α-synuclein polymers: implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies,” The Journal of Biological Chemistry, vol. 275, no. 24, pp. 18344–18349, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Hodara, E. H. Norris, B. I. Giasson et al., “Functional consequences of α-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation,” The Journal of Biological Chemistry, vol. 279, no. 46, pp. 47746–47753, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Snead and D. Eliezer, “Alpha-synuclein function and dysfunction on cellular membranes,” Experimental Neurobiology, vol. 23, no. 4, pp. 292–313, 2014. View at Publisher · View at Google Scholar
  43. J. L. Webb, B. Ravikumar, J. Atkins, J. N. Skepper, and D. C. Rubinsztein, “α-Synuclein is degraded by both autophagy and the proteasome,” Journal of Biological Chemistry, vol. 278, no. 27, pp. 25009–25013, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Ebrahimi-Fakhari, I. Cantuti-Castelvetri, Z. Fan et al., “Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein,” The Journal of Neuroscience, vol. 31, no. 41, pp. 14508–14520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Shi, C. P. Zabetian, A. M. Hancock et al., “Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease,” Neuroscience Letters, vol. 480, no. 1, pp. 78–82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Gao, H. Tang, K. Nie et al., “Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis,” International Journal of Neuroscience, vol. 125, no. 9, pp. 645–654, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Emmanouilidou, K. Melachroinou, T. Roumeliotis et al., “Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival,” Journal of Neuroscience, vol. 30, no. 20, pp. 6838–6851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Lööv, C. R. Scherzer, B. T. Hyman, X. O. Breakefield, and M. Ingelsson, “α-Synuclein in extracellular vesicles: functional implications and diagnostic opportunities,” Cellular and Molecular Neurobiology, vol. 36, no. 3, pp. 437–448, 2016. View at Publisher · View at Google Scholar
  49. M. Grey, C. J. Dunning, R. Gaspar et al., “Acceleration of alpha-synuclein aggregation by exosomes,” Journal of Biological Chemistry, vol. 290, no. 5, pp. 2969–2982, 2015. View at Publisher · View at Google Scholar
  50. C. P. Lai, E. Y. Kim, C. E. Badr et al., “Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters,” Nature Communications, vol. 6, article 7029, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. S. B. Prusiner, “A unifying role for prions in neurodegenerative diseases,” Science, vol. 336, no. 6088, pp. 1511–1513, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Desplats, H.-J. Lee, E.-J. Bae et al., “Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 31, pp. 13010–13015, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Hansen, E. Angot, A.-L. Bergström et al., “α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells,” The Journal of Clinical Investigation, vol. 121, no. 2, pp. 715–725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. K. C. Luk, V. Kehm, J. Carroll et al., “Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice,” Science, vol. 338, no. 6109, pp. 949–953, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. K. C. Luk, V. M. Kehm, B. Zhang, P. O'Brien, J. Q. Trojanowski, and V. M. Y. Lee, “Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice,” The Journal of Experimental Medicine, vol. 209, no. 5, pp. 975–986, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Lelan, L. Lescaudron, C. Boyer et al., “Effects of human alpha-synuclein A53T-A30P mutations on SVZ and local olfactory bulb cell proliferation in a transgenic rat model of Parkinson disease,” Parkinson's Disease, vol. 2011, Article ID 987084, 11 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Aulić, T. T. N. Le, F. Moda et al., “Defined α-synuclein prion-like molecular assemblies spreading in cell culture,” BMC Neuroscience, vol. 15, article 69, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Ulusoy, R. E. Musgrove, R. Rusconi et al., “Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury,” Acta Neuropathologica Communications, vol. 3, article 13, 2015. View at Publisher · View at Google Scholar
  59. A. Abeliovich, Y. Schmitz, I. Fariñas et al., “Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system,” Neuron, vol. 25, no. 1, pp. 239–252, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Chandra, F. Fornai, H.-B. Kwon et al., “Double-knockout mice for α- and β-synucleins: effect on synaptic functions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 41, pp. 14966–14971, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. V. S. Kokhan, M. A. Afanasyeva, and G. I. Van'kin, “α-Synuclein knockout mice have cognitive impairments,” Behavioural Brain Research, vol. 231, no. 1, pp. 226–230, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. T. Wang and J. C. Hay, “Alpha-synuclein toxicity in the early secretory pathway: how it drives neurodegeneration in Parkinsons disease,” Frontiers in Neuroscience, vol. 9, article 433, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. E. H. Norris, B. I. Giasson, H. Ischiropoulos, and V. M.-Y. Lee, “Effects of oxidative and nitrative challenges on α-synuclein fibrillogenesis involve distinct mechanisms of protein modifications,” The Journal of Biological Chemistry, vol. 278, no. 29, pp. 27230–27240, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. G. Yamin, V. N. Uversky, and A. L. Fink, “Nitration inhibits fibrillation of human α-synuclein in vitro by formation of soluble oligomers,” FEBS Letters, vol. 542, no. 1–3, pp. 147–152, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Martinez-Vicente, “Autophagy in neurodegenerative diseases: from pathogenic dysfunction to therapeutic modulation,” Seminars in Cell and Developmental Biology, vol. 40, pp. 115–126, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. F. J. A. Dennissen, N. Kholod, and F. W. van Leeuwen, “The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim?” Progress in Neurobiology, vol. 96, no. 2, pp. 190–207, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Periquet, T. Fulga, L. Myllykangas, M. G. Schlossmacher, and M. B. Feany, “Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo,” The Journal of Neuroscience, vol. 27, no. 12, pp. 3338–3346, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Ulusoy, F. Febbraro, P. H. Jensen, D. Kirik, and M. Romero-Ramos, “Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology,” European Journal of Neuroscience, vol. 32, no. 3, pp. 409–422, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. H.-J. Lee, J.-E. Suk, C. Patrick et al., “Direct transfer of α-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies,” The Journal of Biological Chemistry, vol. 285, no. 12, pp. 9262–9272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. R. M. Rasia, C. W. Bertoncini, D. Marsh et al., “Structural characterization of copper(II) binding to α-synuclein: insights into the bioinorganic chemistry of Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 12, pp. 4294–4299, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Binolfi, R. M. Rasia, C. W. Bertoncini et al., “Interaction of α-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement,” Journal of the American Chemical Society, vol. 128, no. 30, pp. 9893–9901, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. M. G. Cersosimo, “Gastrointestinal biopsies for the diagnosis of alpha-synuclein pathology in Parkinson's disease,” Gastroenterology Research and Practice, vol. 2015, Article ID 476041, 6 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. B. Zhou, M. Wen, W.-F. Yu, C.-L. Zhang, and L. Jiao, “The diagnostic and differential diagnosis utility of cerebrospinal fluid α-synuclein levels in Parkinson's disease: a meta-analysis,” Parkinson's Disease, vol. 2015, Article ID 567386, 11 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Parnetti, C. Cicognola, P. Eusebi, and D. Chiasserini, “Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis,” Biomarkers in Medicine, vol. 10, no. 1, pp. 35–49, 2016. View at Publisher · View at Google Scholar · View at Scopus
  75. T. G. Beach, C. H. Adler, L. I. Sue et al., “Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders,” Acta Neuropathologica, vol. 119, no. 6, pp. 689–702, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. I. Devic, H. Hwang, J. S. Edgar et al., “Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease,” Brain, vol. 134, no. 7, article e178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. K. Yanamandra, M. A. Gruden, V. Casaite, R. Meskys, L. Forsgren, and L. A. Morozova-Roche, “α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of parkinson's disease patients,” PLoS ONE, vol. 6, no. 4, Article ID e18513, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Gámez-Valero, S. I. Lozano-Ramos, I. Bancu, R. Lauzurica-Valdemoros, and F. E. Borràs, “Urinary extracellular vesicles as source of biomarkers in kidney diseases,” Frontiers in Immunology, vol. 6, article 6, 2015. View at Publisher · View at Google Scholar · View at Scopus
  79. L. Zange, C. Noack, K. Hahn, W. Stenzel, and A. Lipp, “Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy,” Brain, vol. 138, no. 8, pp. 2310–2321, 2015. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Tolosa and D. Vilas, “Peripheral synuclein tissue markers: a step closer to Parkinson's disease diagnosis,” Brain, vol. 138, no. 8, pp. 2120–2122, 2015. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Miki, M. Tomiyama, T. Ueno et al., “Clinical availability of skin biopsy in the diagnosis of Parkinson's disease,” Neuroscience Letters, vol. 469, no. 3, pp. 357–359, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Navarro-Otano, J. Casanova-Mollà, M. Morales, J. Valls-Solé, and E. Tolosa, “Cutaneous autonomic denervation in Parkinson’s disease,” Journal of Neural Transmission, vol. 122, no. 8, pp. 1149–1155, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. V. Donadio, A. Incensi, C. Piccinini et al., “Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease,” Annals of Neurology, vol. 79, no. 2, pp. 306–316, 2016. View at Publisher · View at Google Scholar · View at Scopus
  84. T. Lebouvier, T. Chaumette, P. Damier et al., “Pathological lesions in colonic biopsies during Parkinson's disease,” Gut, vol. 57, no. 12, pp. 1741–1743, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. M. G. Cersósimo, C. Perandones, F. E. Micheli et al., “Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients,” Movement Disorders, vol. 26, no. 1, pp. 188–190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. K. M. Shannon, A. Keshavarzian, E. Mutlu et al., “Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease,” Movement Disorders, vol. 27, no. 6, pp. 709–715, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Alexoudi, S. A. Schneider, and G. Deuschl, “Submandibular gland biopsy for the diagnosis of Parkinson's disease,” Movement Disorders, vol. 28, no. 6, p. 734, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. A. W. Schmid, B. Fauvet, M. Moniatte, and H. A. Lashuel, “Alpha-synuclein post-translational modifications as potential biomarkers for parkinson disease and other synucleinopathies,” Molecular & Cellular Proteomics, vol. 12, no. 12, pp. 3543–3558, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. C. H. Adler, B. N. Dugger, M. L. Hinni et al., “Submandibular gland needle biopsy for the diagnosis of Parkinson disease,” Neurology, vol. 82, no. 10, pp. 858–864, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Sanchez-Ferro, A. Rabano, M. J. Catalan et al., “In vivo gastric detection of alpha-synuclein inclusions in Parkinson's disease,” Movement Disorders, vol. 30, no. 4, pp. 517–524, 2015. View at Google Scholar
  91. C. H. Adler, B. N. Dugger, J. G. Hentz et al., “Peripheral synucleinopathy in early Parkinson's disease: submandibular gland needle biopsy findings,” Movement Disorders, vol. 31, no. 2, pp. 250–256, 2016. View at Publisher · View at Google Scholar · View at Scopus
  92. P. Rivero-Ríos, J. Madero-Pérez,, B. Fernández, and S. Hilfiker, “Targeting the autophagy/lysosomal degradation pathway in Parkinson's disease,” Current Neuropharmacology, vol. 14, no. 3, pp. 238–249, 2016. View at Publisher · View at Google Scholar
  93. M. Mandler, E. Valera, E. Rockenstein et al., “Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials,” Acta Neuropathologica, vol. 127, no. 6, pp. 861–879, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. B. Dehay, M. Decressac, M. Bourdenx et al., “Targeting alpha-synuclein: therapeutic options,” Movement Disorders, vol. 31, no. 6, pp. 882–888, 2016. View at Publisher · View at Google Scholar
  95. A. Ciechanover and Y. T. Kwon, “Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies,” Experimental & Molecular Medicine, vol. 47, no. 3, article e147, 2015. View at Publisher · View at Google Scholar
  96. C. McKinnon and S. J. Tabrizi, “The ubiquitin-proteasome system in neurodegeneration,” Antioxidants and Redox Signaling, vol. 21, no. 17, pp. 2302–2321, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. E. Himpe and R. Kooijman, “Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway,” BioFactors, vol. 35, no. 1, pp. 76–81, 2009. View at Publisher · View at Google Scholar · View at Scopus